Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer immunotherapeutics - Ryvu Therapeutics

Next Previous
Drug Profile

Research programme: cancer immunotherapeutics - Ryvu Therapeutics

Alternative Names: GCN2 kinase inhibitor - Ryvu Therapeutics; General control non-repressed 2 kinase inhibitor - Ryvu Therapeutics; HPK1 inhibitors - Ryvu Therapeutics; Stimulator of interferon genes agonist - Ryvu Therapeutics; STING agonists - Ryvu Therapeutics; STING pathway agonists - Ryuv Therapeutics; TCR/TLR pathway modulators - Ryvu Therapeutics

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selvita
  • Developer Ryvu Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EIF2AK4 protein inhibitors; Hematopoietic progenitor kinase 1 inhibitors; STING1 protein stimulants; T-cell receptor antigen modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in Poland
  • 30 Nov 2022 BioNtech in-licenses STING agonist portfolio from Ryvu Therapeutics
  • 10 Nov 2021 Preclinical development is ongoing in Poland

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top